Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Voriconazole plus Micafungin for Invasive Aspergillosis
NCT00423163Phase 4Withdrawn
- Sponsor
- Astellas Pharma
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in invasive aspergillosis (IA) comparing Voriconazole + Micafungin with Voriconazole + Placebo (2 arms). Primary endpoint: Global Success (complete and partial response) at 6 weeks. Planned start Feb 2007; status: withdrawn.
02
Drugs
micafungin
03
Conditions
invasive aspergillosis (IA)
Beyond the preview
Go deeper on NCT00423163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00423163.